As 2025 gets underway, Haleon will start to get a better idea of whether its play in the US erectile dysfunction category with Eroxon can be turned into a reliable revenue stream. The OTC medical device was launched in the second half of last year touted by Haleon as the first Food and Drug Administration-cleared, clinically-proven treatment for ED.
Euro Q4 Consumer Health Earnings Preview: Haleon, Bayer, Reckitt
Major Europe-based consumer health players Haleon, Bayer and Reckitt feature in this sales and earnings preview, which highlights what to look out for as these three firms report their Q4 2024 results over the coming weeks.
